Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy

American Journal of Clinical Nutrition

Volumn 82, Issue 1, 2005, Pages 146-154

  Thomas Geevarghese, Asha ^a   Raghavan, Subhashree ^a   Minolfo, Robert ^a   Holleran, Steve ^a   Ramakrishnan, Rajasekhar ^a   Ormsby, Bernard ^b   Karmally, Wahida ^a   Ginsberg, Henry N ^a   El Sadr, Wafaa M ^a   Albu, Jeanine ^a   Berglund, Lars ^a,b,c,d  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

African Americans; Antiretroviral treatment; ART; HIV; Insulin resistance; NNRTI; Nonnucleoside reverse transcriptase inhibitor; Postprandial lipemia; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LIPID; LIPOPROTEIN; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; CHOLESTEROL;

ADULT; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; ETHNOLOGY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; MALE; MEAL; POSTPRANDIAL STATE; AGED; BLOOD; CLINICAL TRIAL; DIET; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; AGED; BLOOD GLUCOSE; CHOLESTEROL; DIET; ENERGY INTAKE; FEMALE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; REVERSE TRANSCRIPTASE INHIBITORS; TRIGLYCERIDES;

EID: 23444461418     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn.82.1.146     Document Type: Article

References (45)

1. Danner SA, Carr A, Leonard JM, et al, for the European-Australian Collaborative Ritonavir Study Group. Safety, pharmacokinetics and preliminary efficiency of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
2. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338: 853-60.
4. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
5. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294(letter).
6. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337: 734-43.
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
8. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.
9. Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis.' Curr Opin Lipidol 2004;15:59-67.
10. Dube M, Stein JH, Aberg JA, et al, for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-27.
11. Tershakovec AM, Frank I, Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis 2004;174:1-10.
12. Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
13. Hui DY. Effects of protease inhibitor therapy on lipid metabolism. Progress Lipid Res 2003;42:81-92.
14. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J AIDS 2000;23:35-43.
15. Riddle TM, Schildmeyer NM, Phan C, Fichtenbaum CJ, Hui DY. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res 2002;43:1458-63.
16. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2001;2:174-80.
17. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;7:51-7.
18. Martinez E, Domingo P, Galindo MJ, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004;38:1017-23.
19. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-82.
20. Hadigan C, Jeste S, Anderson EJ, Tsay R, Cyr H, Grinspoon S. Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clin Infect Dis 2001;33:710-7.
21. Negredo E, Ribalta J, Ferre R, et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004;18:819-21.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA 2001;285:2486-97.
23. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report to the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
24. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk for myocardial infarction. N Engl J Med 2003;349:1993-2003.
25. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999;131:548(letter).
26. Coplan PM, Nikas A, Japour A, et al. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003;19:449-55.
27. Holmberg SD, Moorman AC, Williamson JM, et al, for the HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
28. Hyson D, Rutledge JC, Berglund L. Postprandial lipemia and cardiovascular disease. Curr Atheroscler Rep 2003;5:437-44.
29. Cohn J. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988;29:469-79.
30. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999;246:341-55.
31. Couch SC, Isasi CR, Karmally W, et al. Predictors of postprandial triacylglycerol response in children: the Columbia University Biomarkers Study. Am J Clin Nutr 2000;72:1119-27.
32. Lewis GF, O'Meara NM, Soltys PA, et al. Fasting hypertriacylglycerolemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 1991;72:934-44.
33. Simon GL, Liappis AP, Granger SL, et al. Antiretroviral therapy-induced changes in lipoprotein subclass phenotype: comparison of protease inhibitor and non-nucleoside reverse transcriptase inhibitor regimens. Antivir Ther 2002;7:L9(abstr).
34. van der Valk M, Kastelein JP, Murphy RL, et al, on behalf of the Atlantic Study. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-14.
35. Dennis BH, Stewart P, Wang CH, et al. Diet design for a multicenter controlled feeding trial: the DELTA program. Delta Research Group. J Am Diet Assoc 1998;98:766-76.
36. Ginsberg HN, Kris-Etherton P, Dennis B, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol 1998;18:441-9.
37. Krauss RM, Eckel RH, Howard B, et al. AHA dietary guidelines. Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Stroke 2000;31:2751-56.
38. Harris J, Benedict F. A biometric study of basal metabolism in man. Washington, DC: Carnegie Institution, 1919.
39. Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein (a) levels: effects of estrogen replacement therapy on lipoprotein (a) and acute phase reactants in post-menopausal women. Arterioscler Thromb Vasc Biol 1997;17:1822-9.
40. van Wijk JP, Halkes CJ, Erkelens DW, Castro Cabezas M. Fasting and daylong triacylglycerols in obesity with and without type 2 diabetes. Metabolism 2003;52:1043-9.
41. Halkes CJ, Van Wijk JP, Ribalta J, Masana L, Castro Cabezas M. Diurnal triacylglycerolemia and insulin resistance in mildly obese subjects with normal fasting plasma lipids. J Intern Med 2004;255:74-81.
42. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriacylglycerolemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27-31.
43. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
44. Grunfeld C, Feingold KR. The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriacylglycerolemia and wasting of AIDS. J Nutr 1992;122:749-53.
45. Shor-Posner G, Basil A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993;94:515-9.